Table 2.
DHEA sulfate immunoassay cross-reactivity
| Compound | Plasma/serum concentrations | Cross-reactivity in Roche assay | Likelihood of clinically significant cross-reactivity |
|---|---|---|---|
| DHEA sulfate |
• Up to 6,070 ng/mL (infants) [31] |
100% |
High (assay target) |
| • 5 – 4,070 ng/mL (females > 1 year old) [31] | |||
| • 5–4,920 ng/mL (males > 1 year old) [31] | |||
| Pregnenolone sulfate |
• 21 – 84 ng/mL (adult controls) [32] |
2.1% |
Low, possible minor effect around time of parturition. |
| • Up to 1,580 ng/mL in pregnancy [33] | |||
| 17-Hydroxyprogesterone |
• 0.1 – 2.0 ng/mL (pediatric controls) [22] |
0.08% |
Low, possible minor effect in 21-hydroxylase deficiency. |
| • Up to 1,005 ng/mL (21-hydroxylase deficiency) [22] | |||
| 17-Hydroxypregnenolone |
• Up to 4.3 ng/ml in healthy females [34,35] |
0.05% |
Low |
| • Up to 4.8 ng/mL in healthy males [34,35] | |||
| • Up to 100 ng/mL in premature infants [36] |